All issues > Volume 38(6); 1995

Original Article

J Korean Pediatr Soc. 1995;38(6):771-777. Published online June 15, 1995.

Immunogenicity and Safety of Live Attenuated Vaccine(MAV/06srtain) on Healthy Children and Immunocompromised Children

Young Mo YM Sohn¹, Chul Joo CJ Yu¹, Pyung Kil PK Kim¹, Kir Young KY Kim¹, Chong Young CY Park², Mi Ran MR Kim², Woo Kap WK Jeung², Kyu Kye KK Hwang³, Gyu Jin GJ Woo³, Song Yong SY Park³

¹Department of Pediatrics, Yonsei University, College of Medicine, Seoul, Korea
¹Department of Pediatrics, Yonsei University, College of Medicine, Seoul, Korea
²Department of Pediatrics, Hanlim University, College of Medicine, Chuncheon, Korea
³Mogam Biotechnology Research Institute, YongIn, Korea

Abstract

Purpose
: To study the safety and immunogenicity of new live attenuated varicella vaccine (MAV/06strain) in normal healthy children and immunocompromized children in Korea.
Methods
: Blood samples for fluorescent antibody to membrane antigen(FAMA) assay were taken before the vaccination among seven hundred forth five healthy children and twenty two nine immunocompromised children. One hundred and seventy seven children and twenty two immunocompromized children(leukemia 6, solid tumor 10, nephrotic syndrome 6) were immunized with live attenuated varicella vaccine(Suduvax). Clinical response were observed after vaccination during the study period.
Results
: Among one hundred and sixty one healthy children who were able to follow up, mild local reactions were developed ; the pain and tenderness in 36 cases(22.4%), swalling and induration in 27 cases(16.8%), redness in 19 cases(11.8%) during first three days after vaccination. Fever developed in 4 cases(2.5%), headche in 4 cases(2.5%), loss of appetite in 3 cases(1.9%), rash with vesicles in 1 case as a geometric mean titre(GMT) was 173.7¡¾29.8, Among eighteen immunocompromised children(leukemia 2, solid tumor 10, nephrotic syndrome 6) who were able to follow up, 3 cases of pain and tenderness(16.7%), 3 cases of swalling and induration(16.7%), 3 case of redness(16.7%) at injection site and 1 case of fever, 1 case of generalized erythematous rash without vesicels were developed. Seroconversion rate of immunocompromised children was 100%(18/18) and GMT was 111.4¡¾19.2. All side reaction subsided spontaneously without any medical teratment.
Conclusions
: This live attenuated varicella varicella vaccine(MAV/06 strain) appear to be well tolerated and highly immunogenic in immunocompromised children as well as in normal healthy children.

Keywords :Immunogenicity, live attenuated Varicella Virus Vaccine, Immuncompromised